Overview

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in combination with Abraxane®/Gemcitabine.

Phase:

Phase 1

Details

Lead Sponsor:

VCN Biosciences, S.L.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel